Measurable Residual Disease in Mantle Cell Lymphoma: The Unbearable Lightness of Being Undetectable.

IF 4.7 2区医学 Q1 ONCOLOGY Current Oncology Reports Pub Date : 2024-12-01 Epub Date: 2024-12-06 DOI:10.1007/s11912-024-01620-8

Julio Cartagena, Anagha Deshpande, Allison Rosenthal, Mazie Tsang, Talal Hilal, Lisa Rimsza, Razelle Kurzrock, Javier Munoz

{"title":"Measurable Residual Disease in Mantle Cell Lymphoma: The Unbearable Lightness of Being Undetectable.","authors":"Julio Cartagena, Anagha Deshpande, Allison Rosenthal, Mazie Tsang, Talal Hilal, Lisa Rimsza, Razelle Kurzrock, Javier Munoz","doi":"10.1007/s11912-024-01620-8","DOIUrl":null,"url":null,"abstract":"Purpose of review: This paper evaluates the benefits and limitations of detecting measurable residual disease (MRD) in mantle cell lymphoma (MCL) and assesses its prognostic value. It also aims to highlight the importance of detecting low MRD levels post-treatment and their application in clinical practice.Recent findings: Recent studies show that MRD levels predict relapse and survival outcomes in hematologic neoplasms, including MCL. RT-qPCR is currently the most used method due to its high reproducibility and sensitivity. Ideal MRD detection should be highly sensitive, cost-effective, and applicable to a wide demographic of patients. This paper concludes that MRD detection has prognostic value in MCL but faces limitations in sensitivity and specificity. Further research is needed to establish the significance of low MRD levels before integrating these methods into clinical practice. Improved MRD detection technologies and understanding their impact on clinical outcomes will guide better patient management in MCL.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"1664-1674"},"PeriodicalIF":4.7000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Oncology Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11912-024-01620-8","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/6 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: This paper evaluates the benefits and limitations of detecting measurable residual disease (MRD) in mantle cell lymphoma (MCL) and assesses its prognostic value. It also aims to highlight the importance of detecting low MRD levels post-treatment and their application in clinical practice.

Recent findings: Recent studies show that MRD levels predict relapse and survival outcomes in hematologic neoplasms, including MCL. RT-qPCR is currently the most used method due to its high reproducibility and sensitivity. Ideal MRD detection should be highly sensitive, cost-effective, and applicable to a wide demographic of patients. This paper concludes that MRD detection has prognostic value in MCL but faces limitations in sensitivity and specificity. Further research is needed to establish the significance of low MRD levels before integrating these methods into clinical practice. Improved MRD detection technologies and understanding their impact on clinical outcomes will guide better patient management in MCL.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

套细胞淋巴瘤中可测量的残留疾病：无法检测的不可承受之轻。

综述目的：本文评价检测套细胞淋巴瘤（MCL）可测量残留病（MRD）的益处和局限性，并评估其预后价值。它还旨在强调治疗后检测低MRD水平及其在临床实践中的应用的重要性。最近的发现：最近的研究表明，MRD水平预测血液学肿瘤的复发和生存结果，包括MCL。RT-qPCR具有高重复性和高灵敏度，是目前应用最多的方法。理想的MRD检测应该是高度敏感的，具有成本效益的，并且适用于广泛的患者。结论：MRD检测在MCL中具有预后价值，但在敏感性和特异性方面存在局限性。在将这些方法应用于临床实践之前，需要进一步的研究来确定低MRD水平的意义。改进的MRD检测技术和了解其对临床结果的影响将指导更好的MCL患者管理。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current Oncology Reports ONCOLOGY-

CiteScore

8.50

自引率

0.00%

发文量

187

审稿时长

6-12 weeks

期刊介绍： This journal aims to review the most important, recently published clinical findings in the field of oncology. By providing clear, insightful, balanced contributions by international experts, the journal intends to serve all those involved in the care of those affected by cancer. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as cancer prevention, leukemia, melanoma, neuro-oncology, and palliative medicine. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.